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Abstract
Genetic risk for depressive disorders is poor-
ly understood despite consistent suggestions of
a high heritable component. Most genetic stud-
ies have focused on risk associated with single
variants, a strategy which has so far only yield-
ed small (often non-replicable) risks for depres-
sive disorders. In this paper we argue that more
substantial risks are likely to emerge from
genetic variants acting in synergy within and
across larger neurobiological systems (poly-
genic risk factors). We show how knowledge of
major integrated neurobiological systems pro-
vides a robust basis for defining and testing the-
oretically defensible polygenic risk factors. We
do this by describing the architecture of the
overall stress response. Maladaptation via
impaired stress responsiveness is central to the
aetiology of depression and anxiety and pro-
vides a framework for a systems biology
approach to candidate gene selection. We pro-
pose principles for identifying genes and gene
networks within the neurosystems involved in
the stress response and for defining polygenic
risk factors based on the neurobiology of stress-
related behaviour. We conclude that knowledge
of the neurobiology of the stress response sys-
tem is likely to play a central role in future
efforts to improve genetic prediction of depres-
sion and related disorders.
Introduction
Twin studies have consistently suggested
high heritability of common mental disorders
(40-50% for depression and anxiety).1 However,
despite significant investment in genome wide
association studies (GWAS) and specific stud-
ies of biologically relevant candidate genes, to
date, progress in understanding the molecular
contribution to these disorders has been slow.1
Even in comparison to other complex diseases,
mental disorders lag behind in terms of under-
standing the underlying genetic mechanisms.
Among the published findings,2 there are few
examples where significant results have been
replicated indicating a propensity within the
field to yield false positives. One of the signifi-
cant challenges of psychiatric genetic research,
and indeed research on complex diseases more
generally, is that risk associated with individual
variants [typically single nucleotide polymor-
phisms (SNPs) >1% prevalence] has been con-
sistently shown to be small.1 This raises impor-
tant methodological challenges around the
detection of variants of small effects and ques-
tions about the applied utility of such variants
when detected. Reliable detection of small
effects is critically dependent high quality and
well powered studies, heterogeneity of which
continues to be a major cause of the lack of
replication in the field.3 Even for genetic vari-
ants with demonstrated functional effects (e.g.
5HTTLPR), cross-study replication has been dif-
ficult and individual functional loci have like-
wise not translated into large effects on risk for
mental disorders.4,5 In this general context of
small effects and associated difficulties with
outcome replication, there has been a growing
interest in other forms of genetic risk that
might have higher aetiological significance. For
example, with enhanced deep sequencing capa-
bilities provided by new generation technolo-
gies, there has been a shift in interest from
common to rare variants on the understanding
that rare variants might play a more substantial
aetiological role in complex disease.6,7
However, even if higher predictive values are
observed for rare variants, these would only
apply to a small proportion of the population
and arguably are characterised by more
extreme clinical phenotypes. It would provide
little insight into the genetic determinants of
the more common mental disorders, which
drive the global burden of disease. Another
idea, which has applicability to a broader range
of phenotypes, has attracted considerable atten-
tion: synergistic actions between multiple
(common) loci of small effect may define more
substantial genetic risk for common mental dis-
orders. This has lead to interest in assembling
SNPs into SNP composites, or more precisely,
polygenic risk pathways.8 The essential idea is
that joint effects have the potential to confer
aetiological impacts beyond the sum of their
individual parts.9-13 The importance of integrat-
ed approaches to investigate composite genetic
risk is gaining increasing leverage in other
areas (such as cancer genetics) and methodol-
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ogy development is an active field of research.14
However, in the presence of millions of variants
available within for example a GWAS dataset,
and billions of unique combinations between
variants, the challenge is develop methods that
enable identification of polygenic risk factors.
One approach is to use conventional interac-
tion models to atheoretically scan for interac-
tion between variants within, for example, a
GWAS dataset. The problem with this approach
is that sample size requirements and multiple
testing burdens increase exponentially with
interaction complexity and place severe con-
straints on investigations. This limit is funda-
mental and cannot be avoided by purely statisti-
cal means.15 An alternative is to examine cumu-
lative effects by summing risk alleles to create
a continuous profile score. This polygenic pro-
file can then be associated with phenotypes of
interest.16 Profile scoring was pioneered in the
context of GWAS by Wray and co-workers and
represents a do-able way of commencing inves-
tigations into polygenic effects while other
methodologies continue to be developed.17
Polygenic profiling is particularly suited to
investigations within well defined biological
fields, such as the study of specific apoptosis
pathways in cancer and growth pathways pre-
dicting birth weight.18,19 This strategy is
informed by a systems biology approach. The
neurobiology of the stress response is a well-
defined biological system capable of providing
robust guidance to profile scoring methods for
investigating polygenic risk factors relevant to
common mental disorders. A systems biology
approach brings additional advantages to
research on complex disease: i) it reduces
multi-testing burden by restricting the focus of
analysis to meaningful biological pathways and
ii) it provides a basis for identifying genes and
gene networks of higher aetiological impact
because of their position and role within known
biological pathways.3 The purpose of this
review is to describe how knowledge of major
integrated neurobiological systems underlying
stress-related behaviour could be used to guide
a systems biology approach to identifying and
testing theoretically defensible polygenic risk
factors for common mental disorders - in partic-
ular, depressive and anxiety disorders. To do
this, we first describe the physiological archi-
tecture of major neurobiological systems under-
lying the regulation of stress responsiveness
and stress-sensitive behaviour: the
Hypothalamic-Pituitary-Adrenocortical (HPA)
axis, the Meso-Corticolimbic System (MCLS),
the Hindbrain Autonomic Regulatory System
(HARS) and the Renin-Angiotensin System
(RAS). We then describe four principles for can-
didate gene selection, which is based on the
cumulative weight of evidence for the role of
the gene products in each of these neurosig-
nalling systems and as part of their interac-
tions. 
Neurobiological systemsimportant to stress-sensitivemood regulation
Mental health relies on the ability to regu-
late cognition, to control emotion and behav-
iour and to cope with stress. The HPA axis, the
MCLS, the HARS and the RAS have all been
implicated in the management of executive
cognitive functioning, behavioural inhibition
and emotional and stress reactivity.20 Pivotal
neurotransmitters involved in these systems
are dopamine (DA), serotonin (5HT), norepi-
nephrine (NE), epinephrine (E) and g-
aminobutyric acid (GABA). Other indispensa-
ble neuroactive peptides and hormones are
angiotensin (ANG) II, corticotrophin releasing
hormone (CRH), arginine vasopressin (AVP),
cortisol (CORT) and adrenalin. There is clear
overlap in forebrain target sites of innervation
by these signalling systems (Figure 1A).
Furthermore, the mode of action of each of
these systems is particularly sensitive to
stress. Together, these signalling systems form
the basis of an intricate network that links the
corticolimbic system to the hypothalamus in
the forebrain, the autonomic regions in the
hindbrain and stress hormone secreting
glands outside the brain (Figure 1B) to control
mood and its associated behaviour. The hypothalamic-pituitary-adrenocortical axis
Psychological stress plays an important role
in the aetiology of mood disorders and tends to
result in hyperactivity of the HPA axis, which
elevates the level of the stress hormone CORT
in the circulation (Figure 1B). This neuroen-
docrine phenomenon is frequently observed in
various forms of depression and anxiety and
explains why these specific mental health ill-
nesses are often referred to as stress-related
disorders associated with impaired regulation
of stress hormones.21
The cortex of the adrenal glands is the pri-
mary site of biosynthesis of CORT. Regulation
of CORT synthesis and release by the adrenal
glands commences with synthesis of CRH in
the parvocellular neurons of the paraventricu-
lar nucleus in the hypothalamus of the fore-
brain (Figure 1B).22,23 CRH is released into the
portal blood system around the pituitary gland,
where it binds to CRHR1 receptors on a specif-
ic type of cells within the anterior subdivision
of the pituitary, the corticotrophic cells. Here,
binding of CRH to its receptors triggers the
expression of pro-opiomelanocortin and the
release of its derivative adrenocorticotrophic
hormone (ACTH) into the blood circulation. In
turn, ACTH can reach the adrenal glands situ-
ated on top of the kidneys, to stimulate the
release of CORT from the adrenal cortex.
Corticosteroid binding globulin (CBG) in blood
is able to temporarily inactivate CORT, which
identifies a distinct level of regulation of func-
tional CORT available for biological action in
the stress response system. If not bound to
CBG, CORT can easily move from blood into
brain tissue across the blood-brain barrier
(BBB), where it binds to 2 types of corticos-
teroid receptors; the mineralocorticoid recep-
tor (MR) and the glucocorticoid receptor
(GR).24 MR has the highest affinity for CORT
and is predominantly localised in the hip-
pocampus, amygdala and prefrontal cortex,
important corticolimbic brain regions in the
appraisal of stress and initiation of a stress
response if needed. Although GR is more wide-
ly distributed throughout the brain, its
strength to bind CORT is about 10-fold lower
compared to MR. CORT binding to MR and GR
in the hippocampus and prefrontal cortex indi-
rectly inhibits CRH biosynthesis in the hypo-
thalamic paraventricular nucleus via intercon-
nections of mostly GABA-ergic interneurons
between these forebrain regions.25 As a conse-
quence, overall HPA activity decreases and
reduces CORT synthesis and release. This type
of autoregulation of CORT ensures termina-
tion of the stress response when the triggering
stimulus is no longer there. 
Under conditions of severe and chronic
stress, the parvocellular CRH neurons in the
paraventricular nucleus can produce even
more arginine vasopressin, which acts as an
additional stimulus for ACTH release via spe-
cific V1b receptors on corticotrophic cells in
the anterior pituitary.26,27 Sustained stress also
compromises the inhibitory role of the hip-
pocampus on the HPA cascade of neuroen-
docrine events via downregulation of MR and
GR and in the long run reduced hippocampal
neurogenesis.28,29 Furthermore, stress triggers
a CRH producing neuronal system outside the
hypothalamic paraventricular nucleus (Figure
2A), where CRH accessibility to its neural
receptors is regulated by CRH binding protein
(CRH-BP).22 Of particular importance to HPA
regulation are the CRH projections from the
central amygdala to the paraventricular nucle-
us, which stimulate hypothalamic CRH synthe-
sis.23,30 Yet CRH signalling is not limited to
HPA regulation; CRH also influences other
types of brain function as part of the overall
stress response. CRH neuromodulatory effects
in the hindbrain influence NE projections from
the locus coeruleus to the forebrain resulting
in enhanced arousal and vigilance (Figure 2A).
If dysfunctional, this pathway can contribute to
depression and anxiety. Similar local sig-
nalling effects of CRH on neurotransmission
in amygdala and the midbrain ventral tegmen-
tal area and dorsal raphe nucleus are also
implicated in anxiety behaviour and enhanced
sympathetic nervous activity in response to
stress.22,23
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The meso-corticolimbic system 
Connectivity between the midbrain and the
limbic system in the forebrain is crucial for
higher brain functions involved in the regula-
tion of stress sensitive mood states. Distinct
MCLS projections, as part of a larger monoa -
mine neurotransmission system in the brain,
include DA and 5HT pathways originating in
the midbrain and projecting anteriorly (in a
forward direction) to selected limbic and
frontal cortical regions (Figure 1A; blue projec-
tions-DA/red projections-5HT). These projec-
tions typically function in those brain cir-
cuitries responsible for cognition, regulation
of emotion, behaviour, motivation and reward
besides movement. 
The DA pathways within the MCLS of most
interest to mood control are the meso-limbic
and the meso-cortical projections from the
ventral tegmental area in the midbrain. These
either target the limbic network of interactions
between the nucleus accumbens, amygdala,
hippocampus and ventral striatum or extend
further anterior to the prefrontal cortex among
other frontal cortical regions involved in exec-
utive functioning (Figure 2B).31 These specific
DA projections play an important role in moti-
vational behaviour and are thought to under-
pin the incentive, preparatory or acquisition
aspects of reward based behaviours.32-34
Reward deficit due to compromised function of
the mesolimbic DA pathway has been associat-
ed with addiction disorders and may play a key
role in ahedonia (the inability to experience
pleasure), which is a diagnostic feature of
depression.20,23
Biosynthesis of DA for MCLS neurotrans-
mission takes place in the ventral tegmental
area and relies on neuronal uptake of the
amino acid precursor tyrosine, which is
hydroxylated into dihydroxy-l-phenylalanine
(DOPA) by tyrosine hydroxylase (TH). Final
processing of DOPA by DOPA-decarboxylase
(DDC) generates the neurotransmitter DA.
Metabolism of DA within the presynaptic ter-
minus is attained by monoamine oxidase A
(MAO-A) activity, whereas catechol-oxymethyl-
transferase (COMT) metabolises DA mostly in
the synaptic cleft. These catabolic enzymes are
present in all forebrain target regions of the
MCLS. They are also synthesised in the ventral
tegmental area and feed forward projection
loops exist from cortical regions like the pre-
frontal cortex (PFC) back to the midbrain. 
Reuptake of DA as a means to regulate DA
availability for neurotransmission is achieved
by specific Na+/Cl– dependent DA transporters
(DAT). A low density of DA transporters in the
prefrontal cortex allows diffusion of synaptic
DA into other cortical and subcorticical regions
not directly targeted by the meso-corticolimbic
DA projections.35 Reception of DA at the post
synaptic cleft relies on binding to specific DA
receptors [D1-like receptors (DRD1, 5) and
Review
Figure 1. Signalling pathways responsible for stress responsiveness, emotional behaviour
and adaptation. A) Forward (anterior) signalling pathways originating in the midbrain
(light and dark blue: dopamine-ergic/red: serotonin-ergic) and the hindbrain (green: nor-
epinephrine-ergic) and projecting to major corticolimbic forebrain regions. B) the stress-
sensitive cascade of neuroendocrine events along the hypothalamic-pituitary-adrenal axis.
The red areas represent the hypothalamus, the anterior pituitary and the adrenal cortex
respectively from top to bottom. The insert in the top left corner represents a coronal view
of the human brain at the level of the hypothalamus, where the paraventricular nucleus
(red triangles) symmetrically flanks the 3rd ventricle at the base of the brain. Cortisol
(blue dots), as the end product of the hypothalamic-pituitary-adrenal axis, is partly
buffered in the circulation by corticosteroid binding globulin (dark blue caps). 
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D2-like receptors (DRD2, 3, 4)].36 These G-
protein coupled transmembrane receptors are
either located: i) on postsynaptic terminals of
interconnecting neurons that establish synap-
tic neurotransmission within functional corti-
colimbic networks, or ii) on a wider range of
forebrain neurons sensitive to neuromodula-
tion by DA. All types of DA receptors are pres-
ent in corticolimbic DA target regions, albeit in
different configurations per region; however,
the meso-corticolimbic circuitry related to
mood regulation does not seem to include spe-
cific autoreceptors (mostly D2-like in the rat
brain) in the human midbrain ventral tegmen-
tal area region for direct feedback. 
The 5HT pathways within the MCLS, impor-
tant to mood control, arise in selected raphe
nuclei (dorsal raphe and raphe magnus) of
the midbrain and project to a series of limbic
and cortical regions linked to regulation of
emotion, memory and focussed attention
(Figure 1A).37,38
Biosynthesis of 5HT is similar to DA; it is
reliant on the neuronal uptake of tryptophan,
which is converted to the intermediate
metabolite 5-hydroxytryptophan by tryptophan
hydroxylase (TrH) before being processed by l-
aromatic acid decarboxylase to 5HT, the sig-
nalling factor specific to this neurotransmis-
sion system. Metabolism of 5HT is achieved by
enzymatic activity of MAO-A, which metabolis-
es the neurotransmitter into its inactive
metabolite 5-hydroxyindolacetic acid (5HIAA)
among others. Moreover, 5HT, like DA, has the
ability to influence signal transduction in the
corticolimbic system as: i) a neurotransmitter
of interconnected neurons of a functional cir-
cuit, and ii) a neuromodulator via more wide-
spread diffusion of 5HT in limbic and frontal
brain regions linked to regulation of mood and
motivation. 
Reuptake of 5HT by the presynaptic neuron
regulates the availability of 5HT in the synap-
tic cleft and is most specifically controlled by
the 5HT transporter (5HTT) mediating presy-
naptic neuronal reuptake of 5HT. Genetic vari-
ance in the human 5HTT gene in combination
with environmental stimuli has been implicat-
ed in the development of depression.39-41 In
particular, abuse in childhood has been impli-
cated in the development of depression in
adulthood: individuals who are homozygous
for the risk 5HTT allele and who also suffered
abuse in childhood, have been reported to have
a three-fold increase in their risk of major
depression in adulthood (Caspi et al., 2003).
Although alternative studies have confirmed
this adverse gene x environment interaction
effect and the finding remains supported by
some,39-42 it is disputed by others.4
Reception of 5HT is achieved by a family of
transmembrane receptors characterized by
diversity in both species and brain region spe-
cific isoforms (5-HT1A, B, 2A, 3-7). 5HT1
Review
Figure 2. Schematic signalling pathways between various brain regions of the forebrain
corticolimbic network, the forebrain hypothalamus, the midbrain and the hindbrain.
These signalling pathways specifically relate to A) the neuroendocrine response to stress.
Arrows: blue - corticotrophin releasing hormone, red - adrenocorticotrophic hormone,
dark grey - arginine vasopressin, dashed red - cortisol negative feedback action, dashed
black-various indirect neuromediators/solid  stars: red - glucocorticoid receptor, yellow -
mineralocorticoid receptor/open circles: red - cortisol, light blue - corticotrophin releas-
ing hormone, large dark blue - corticosteroid binding globulin, large middle blue - corti-
cotrophin releasing hormone BP/ solid dots: middle green - adrenalin. B) The cate-
cholamine projections within the mesocorticolimbic circuitry. Arrows: purple - targeted
dopamine projections, dark green - targeted serotonin projections/solid dots: purple - dif-
fused dopamine, dark green - diffused serotonin. C) The hindbrain autonomic response
system and the renin angiotensin system. Arrows: light green: targeted norepinephrine
projections,  red - adrenocorticotrophic hormone targeting the adrenal medulla, dashed
middle green - indirect epinephrine-projection via the sympatho-adrenal medulla
axis/solid dots: orange - peripheral angiotensin II, yellow - brain angiotensin II. The neu-
rophysiological detail outlined in the conceptual flowcharts is predominantly based on
fundamental studies performed in rodent models, which over time have been comple-
mented by supportive clinical research and neuropharmacological studies in humans,
underscoring the high degree of similarities in cognitive brain function underlying emo-
tion and behaviour across species.
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receptors typically mediate a suppressive
effect on neuronal firing. Receptor type 5HT1A
is predominantly postsynaptic and abundantly
present in forebrain regions such as prefrontal
cortex, hippocampus, amygdala and lateral
septum. It also functions as an autoreceptor on
5HT synthesizing neurons in the dorsal raphe
and raphe medium region of the midbrain.
5HT1B receptors have been identified in the
rat brain but not in the human brain.43 In con-
trast to 5HT1 receptors, 5HT2-7 receptors tend
tomediate stimulatory 5HT influences on neu-
ronal activity in the prefrontal cortex, hip-
pocampus, amygdala, nucleus accumbens and
the hypothalamus. It is worth noting though
that 5HT target regions may contain neurons
with similar numbers of suppressive (5HT1)
and stimulatory (5HT2-7) receptors. Here, the
polarisation state of the neuron at the time of
5HT signalling will determine its overall neu-
roactive impact via the various types of 5HT
receptors on the same neuron. The hindbrain autonomic regulatorysystem
Two essentially different types of projections
within the HARS contribute significantly to
stress-sensitive mood regulation: i) the NE
projections from the hindbrain forward to fore-
brain, which take part in stress related alert-
ness and memory processing, and ii) the E pro-
jections from hindbrain via the spinal cord out
to the periphery, which are instrumental for
the stress-induced fight-or-flight response
(Figure 2C). 
Part of the anterior NE projections from the
locus coeruleus in the hindbrain to the pre-
frontal cortex, hippocampus and septum are
functionally implicated in memory and anxi-
ety-related behaviour. Others from the NE-rich
A2 cell group of neurons in the hindbrain soli-
tary tract nucleus strongly innervate the amyg-
dala, resulting in distinct enhancement of
memory processing of emotionally loaded
events (Figure 2C).
Biosynthesis of NE occurs in specific cate-
cholaminergic neurons, which synthesise DA
but unlike DA-neurons are able to convert DA
into NE in the presence of dopamine b-hydrox-
ylase within specific intracellular vesicles of
the catecholaminergic neuron.44 Metabolism
of NE is controlled by MAO-A and COMT in a
similar manner to that of DA. Likewise, neu-
ronal reuptake of NE is carried out by NE trans-
porters (NET), which function like DATs. 
Reception of NE is mediated via a and b-
type adrenergic receptors, which have brain
region specific expression patterns: a1 and a2-
adrenergic receptors are detected in abun-
dance in the PFC, while the HC, A and SE con-
tain higher densities of b-adrenergic recep-
tors. The significance of NE signalling via b-
adrenergic receptors in memory processing is
highlighted by the indication that b-adrener-
gic receptor blockers can play a therapeutic
role specifically in posttraumatic stress disor-
der, which is characterised by traumatic mem-
ory retrieval followed by enhanced emotional
responsiveness under non-threatening cir-
cumstances.29 The action of b-blockers is
believed to inhibit with NE neurotransmission
in the basolateral amygdala to negatively
impact on the consolidation of emotionally
loaded memories of stressful events.
A significantly different group of cate-
cholaminergic neurons within the HARS
express the enzyme phenylethanolamine-N-
methyltransferase (PNMT) in addition to all
other components of catecholamine biosynthe-
sis pathway. PNMT allows the conversion of NE
into epinephrine. These neurons are part of
the sympatho-adrenal medulla (SAM) axis, a
series of interconnections from the hindbrain
via the spinal cord to the adrenal medulla
(Figure 2C).25 The SAM axis represents the
primary controller of adrenaline release from
the adrenal medulla, which acts as the stress
hormone of stress-induced cardiovascular
function among other actions of the autonom-
ic nervous system. The HPA axis mediator
ACTH can also stimulate adrenaline release
under stressful circumstances, albeit to a less-
er degree (Figure 2C). Typically being a
peripheral effecter of the SAM axis, adrenaline
cannot easily cross the BBB. Yet indirectly,
stress-induced adrenaline can enhance NE
signalling from the hindbrain to the amygdala
via stimulation of the vagus nerve and conse-
quent solitary tract nucleus activation to con-
tribute to emotionally loaded memory process-
ing via the amygdala in response to stress
(Figure 2C).44The renin angiotensin system 
The RAS is the least characterised neural
signalling system of interest to mood regula-
tion and is better known for its role in regulat-
ing blood pressure and water and salt retention
through ANG II. Peripherally generated ANG II
is known to influence the brain by crossing the
BBB in the circumventricular organs, a select-
ed group of brain regions containing leaky cap-
illaries with compromised barrier function
(Figure 2C);45 however, there is growing evi-
dence of the existence of a distinct brain RAS.
Biosynthesis of Ang II starts with enzymatic
cleavage of its precursor angiotensinogen into
ANG I by renin. Angiotensin converting
enzyme (ACE) then processes ANG I into a
shorter 8 amino acid long peptide ANG II
(sometimes also referred to as ANG-(1-8)).
Various aminopeptidases are able to convert
ANG II into even shorter but still bioactive
angiotensin peptides (ANG III, IV and ANG-(1-
7)), each differing slightly in amino acid
sequence. Metabolism of ANGs is catalysed by
endopeptidases. Most evidence for brain ANG
II biosynthesis and release has been derived
from analysis of RAS activity in the hypothala-
mus.46 Reception of brain ANG II is accom-
plished by ANG receptors (AT1 and AT2)47
throughout the central nervous system. This
distribution pattern includes strategic brain
regions involved in cognition and emotion, like
the hippocampus, amygdala, septum and pre-
frontal cortex.48
Whether brain ANG II and its shorter deriv-
atives should be classified as neurotransmit-
ters awaits confirmation on the intraneuronal
expression and formation of all RAS compo-
nents. Nonetheless, as neuromodulators, the
influence of brain ANGs appears to go beyond
its classical involvement in cardiovascular con-
trol through regulation of sympathetic nerve
activity.49 Recent studies have highlighted
their functional contribution to the regulation
of stress, emotional behaviour and aspects of
cognitive functioning.46,50-53 Moreover, the best
angiotensinergic pathway described in the
hypothalamic paraventricular nucleus (PVN)
directly affects the functional circuitry under-
lying stress and adaptation (Figure 2C).52,53
Recent evidence from animal studies supports
a role for the stress-sensitive brain RAS in co-
regulating hypothalamic CRH expression and
in turn facilitating secretion of ACTH from the
pituitary.52,53
Integrated networks: thinkingacross systems
Optimal neurotransmission within the
MCLS and NE hindbrain projections to the
forebrain require exposure of the brain to
CORT levels within a normal range.29 The
wide-ranging influence of CORT on the control
of cognition, emotion and behaviour is made
possible by the presence of corticosteroid
receptors (MR and GR) throughout the brain
and within all major neurotransmission sys-
tems underlying mood regulation.28,54
Likewise, the location of stress-sensitive CRH
and ANG II synthesis, release and reception
appears to overlap considerably with the MCLS
and the HARS. 
A sudden change from non-stressful to
stressful conditions induced by acute stress
triggers the corticolimbic forebrain system to
appraise the stress stimulus and initiate an
overall stress response. This sets in motion
almost simultaneously a series of related
events that involve all neurobiological systems
described in section 1:
SAM axis activation within HARS stimulating
adrenaline release to mediate the fight or
flight response to stress;25
HPA axis activation resulting in enhanced
availability of CORT in the periphery and
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brain to stimulate the production of glucose
as an energy source in the response to
stress as well as to enhance cerebral alert-
ness and appraisal of the stressor for an
appropriate stress response;28,54
Extrahypothalamic CRH activation resulting in
elevated CRH synthesis and release from
the amygdala projections to the hypothalam-
ic paraventricular nucleus to sustain stress-
induced activation of the HPA axis;55
RAS activation to enhance renin secretion
leading to more centrally available ANG II
contributing to stress-induced activation of
the HPA axis;50
MCLS activation to release additional DA and
5HT in the forebrain;23,56
HARS activation to enhance NE release in the
forebrain.57
The overall stress response also includes
powerful interactive actions in the brain to
increase the impact of some of these stress-
induced events:
Stress-induced SAM axis activation within
HARS augments NE release in the amygdala
via indirect stress-induced adrenaline
effects on the solitary tract nucleus in the
hindbrain;25
Stress-induced HPA axis activation boosts the
NE effect on improving memory processing
of emotionally loaded events by stress-
induced CORT action in the amygdala;29,54
Stress-induced MCLS activation further
increases diffusely available DA in the corti-
colimbic system providing more opportunity
for NETs to internalise DA for deamination
into NE,58 which adds to NE neurotransmis-
sion in the forebrain already enhanced by
stress;
Stress-induced HPA axis activation eventually
terminates the stress response directly via
CORT binding to GR within the HPA axis but
also indirectly via CORT binding to GR
throughout the hippocampus, prefrontal cor-
tex and other GR-rich forebrain regions that
contribute to the MCLS.29,54
Under healthy conditions, a successful
stress response may therefore temporarily
exceed the normal range of CORT and other
stress mediators, but this is usually followed by
an efficient return to baseline activity of all
systems when the stressful stimulus no longer
exists and has been dealt with. The overall ini-
tiation and termination of stress responsive-
ness in the brain seems primarily dependent
on CORT’s mode of action via a balanced ratio
of the MR and GR present in the integrated
network of neuroactive signalling systems
underlying in mood regulation.28,54,59
Persistent exposure to stress tends to reverse
these effects, which can lead to damage in the
brain beyond repair of which hippocampal
degeneration is a well known example.23,28,29
Psychological stress underlying mood disor-
ders tends to be of chronic nature and has
been shown to result in long term HPA axis
activity exceeding the normal range (Holsboer
and Ising, 2009. Data not shown). Evidently,
such chronic exposure to relatively high CORT
relates strongly to psychological dysregulation
(i.e. the inability to control emotion, behaviour
and cognition).20 This suggests that impaired
regulation of stress hormones may directly
impair MCLS and HARS functioning, creating
neurodeficiencies causally linked to stress-
related psychopathology. Clearly, powerful
interactions between the neuroendocrine
stress response systems (the HPA and SAM
axis, the RAS) and the MCLS and HARS under-
lying regulation of mood related cognition,
emotion and behaviour, necessitate an inte-
grated network approach to further entangle
the complexity of depression and anxiety. 
One important application of a systems biol-
ogy approach is in theoretically grouping SNPs
identified by genome-wide association studies
of depressive symptoms into biologically
meaningful polygenic profile scores that can
be tested in genetic epidemiological designs.
For example, 3 of 6 genes replicated in a meta-
analysis of genetic predictors of major depres-
sive disorder (MDD) are in stress response
pathways as described: DRD4, SCL6A3 and
SCL6A4.60 Additionally, 2 of 4 four genes iden-
tified in a 2011 systematic review of genes
associated with MDD, and replicated using
genome wide data from the Genetic
Association Information Network study,61 are
also in stress response pathways as described:
SCL6A2, ACE. To date there has been little
attempt to piece these replicating findings
together into larger polygenic mechanism.
This is largely due to uncertainty about how to
do so. A systems biology approach avoids the
substantial multiple testing burden associated
with atheoretical testing of combinations of
SNPs in genome-wide design. It also provides
a means of testing more complex polygenic
mechanisms than the two-way interactions
typically tested in genome-wide designs. In
this way, a systems biology approach provides
an important framework for putting the pieces
delivered by GWAS together in an integrated
(polygenic) way.
Principles for prioritising genesand gene networks
Neurobiological knowledge of the stress
response systems can work in parallel with
genome-wide approaches by providing another
strategy to identifying (prioritising) genes or
composites of genes for investigation within
genetic association designs. In particular, neu-
robiological knowledge of the stress response
could be used to prioritise genes for more in
depth investigation than genome-wide mark-
ing can provide. This could extend to next gen-
eration sequencing of genes that play rate-lim-
iting roles in neurosignalling within stress
response pathways. It could also extend to
other determinants of gene expression, includ-
ing epigenetic regulators (see below for fur-
ther discussion).
Based on a considered analysis of the bio-
logical architecture of the stress-response sys-
tems, we propose four considerations (or prin-
ciples) for theoretical selection of genes with
intrinsic variations that are likely to influence
the risk for mood regulation disorders; howev-
er, we acknowledge that this is not exhaustive.
In what follows we describe each principle for
theoretical candidate gene prioritisation and
provide examples. Notably, these principles
highlight specific aspects of genes, in which
polymorphisms can compromise the function-
ality of encoded signalling and other types of
proteins that act within individual systems of
the integrated network regulating the overall
stress response. In turn, a polygenic risk for
depressive symptoms can be the additive out-
come of independent smaller genetic effects in
any of the four neurosignalling systems of
interest, or the result of direct gene x gene
interactions underpinning compromised neu-
rosignalling. Genes controlling rate limitingsteps in biosynthesis that have noknown compensatory mechanism 
Some rate limiting steps have compensatory
mechanisms; hence, a functional genetic
mutation in one system may be masked by
genetic counterbalance in another. This phe-
nomenon is referred to as gene redundancy in
genetically manipulated mouse models, in
which compensation of aberrant gene function
masks the phenotypic outcome of the genetic
manipulation of interest.62 However, genes
that function across defined neurosignaling
pathways, generally lack functional backups,
highlighting the need for sequence and func-
tional integrity. A good example of such a piv-
otal gene is TH in the MCLS. TH regulates the
rate-limiting step in the biosynthesis of DA.
Although its pivotal role to hydroxylate tyrosine
parallels the activity of TrH to hydroxylate tryp-
tophan in the early steps of monoamine
biosynthesis and within the MCLS, TH could
replace TrH in the rare absence of TrH to pre-
vent 5HT depletion in the brain, it has no
known compensatory mechanism itself. This
highlights a key role for TH in overall brain
monoamine neurosignalling. Genes for which the gene productis the target of effective medicinaltreatment of mood disorders 
Selective serotonin reuptake inhibitors
(SSRIs), which operate on the MCLS, are
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widely prescribed as anti-depressants, which
operate on the MCLS. SSRIs target the 5HT
signalling system at the level of 5HT reuptake
by 5HTT at the presynaptic end of 5HT neurons
in the brain to prevent any unnecessary loss of
functional 5HT in the synaptic cleft. The
importance of 5HTT in the regulation of 5HT
availability for postsynaptic reception in the
MCLS has been long recognised.40 Similarly,
MAO-A inhibitors are geared towards enhance-
ment of functional 5HT for neurotransmission.
Both 5HTT and MAO-A have already been
intensively studied as candidate genes for
gene-environment interactions with early life
stress in depression;39,41 however, their capac-
ity to individually act as biomarker for depres-
sion risk remains equivocal.4,42 Another MCLS
gene product targeted by mood-regulatory
medication would be the 5HT1A receptor as a
common target site for anxiolytic drugs.37
Within the HARS system, candidate genes can
be prioritised by their gene products being
drug targets for the NE-selective tricyclic anti-
depressants, which serve as a blocker of NET
activity in the reuptake of NE to prolong NE
clearance from the synaptic cleft and reduce
the availability of functional NE for neuro-
transmission. Within the RAS, ACE inhibitors
and AT1 receptor antagonists among other
anti-hypertensive drugs, appear to reverse cog-
nitive decline and signs of depression in anx-
ious patients with high blood pressure.63
Antiglucocorticoid compounds acting as corti-
costeroid receptor antagonists within the HPA
axis have been tested for their antidepressant
activity specifically in psychiatric patients with
elevated HPA activity and animal models of
this condition.24,26,64 Such therapy highlights
the indispensable role of GR in mediating
CORT effects on brain and neuroendocrine
function. Some depressed or anxious patients
with elevated HPA activity also appear to bene-
fit from CRHR1 receptor antagonists blocking
CRH action in the hypothalamus among other
CRH positive brain regions.26 Genes that directly influence morethan one neurobiological systemrelevant to mood regulation 
The best example of a gene that expresses a
neuronal component which functions across
all systems underlying mood regulation is the
GR. Its widespread presence throughout the
brain regions of neurosignal origin and inner-
vation in the MCLS, HARS, RAS, SAM axis and
HPA axis creates an overall sensitivity to
CORT, which can turn into an overall vulnera-
bility to psychological stress in mood related
depression and anxiety.24,25,29 CRH expression
in the hypothalamic paraventricular nucleus
but also a wide range of extrahypothalamic
brain regions involved in MCLS and HARS
function allows the stress-sensitive neuropep-
tide CRH to regulate more than one mood
related neurobiological system. Finally, NE-
selective NETs within the HARS also appear
capable of taking up DA in a NE neuron within
the corticolimbic system for further processing
into NE.58 By being able to target one of the
effectors of the MCLS, a dual role for NETs in
forebrain target regions of the MCLS and the
HARS is highlighted.Genes for which selected polymor-phisms contribute to enhanced riskfor atypical mood regulation basedon empirical considerations
Previous genetic association studies have
reported specific polymorphisms in various
genes encoding for key mediators of the inte-
grated network described in this review, to
raise the odds of exhibiting adverse mental
health behaviour. A recent review of GWAS
with relevant outcomes for a broad range of
psychiatric disorders lists genes like MAO-A,
5HTT and SLC6A4 as candidates for involve-
ment in the neurobiology underpinning
depressive symptoms.1 Functional studies with
a focus on the impact and mechanism of action
of individual gene variations on depression
and anxiety provide evidence in support of a
key role for genes like COMT, 5HTT, ACE, MR
and GR.39,65-67 Based on previous study out-
comes, such genes could continue to be priori-
tised in future candidate gene studies.
Demonstration of a systemsbiology approach
We have tested the potential value of theo-
retical and systems biology driven prioritisa-
tion of gene combinations in our recent study
on the polygenic risk for stress-related traits of
depression and anxiety in the Western
Australian Pregnancy (Raine) cohort.68 To trial
the application of the proposed systems biolo-
gy approach to candidate gene selection with-
in the integrated neuro-network in the brain,
we utilised the four principles previously
described with emphasis on genetic predictors
with the highest likely aetiological signifi-
cance to mood disorders. We defined an early
endophenotypic outcome based on the toddler
temperament score (TTS);69 assessed at one
year of age and strongly associated with atypi-
cal HPA function in late adolescence.
Significant associations were then demon-
strated with SNPs in NR3C1 (the gene encod-
ing for GR) and SLC6A4 (the gene encoding for
5HTT). These effects were limited to male par-
ticipants in the Raine cohort. The magnitude
of impact of the number of adverse alleles in
the specific SNP in NR3C1 on the toddler tem-
perament sub-score for rigid and reactive
behaviour was surprising, accounting for
changes of up to two standard deviations in the
TTS sub-score. Notably, a multi-gene profile
scoring approach incorporating three specific
polymorphisms in NR3C1 and SLC6A4 (coded
for risk and adjusted for independent non-
genetic factors) provided the strongest effect
sizes with increasing number of adverse alle-
les being associated with adverse changes in
the TTS sub-score of up to 3 standard devia-
tions.68 A similar use of polygenic risk analysis
could incorporate another example of syner-
gistic hormone action at the interface of the
HPA axis and HARS within the integrated neu-
ronetwork discussed. In the amygdala, stress-
induced CORT binding to GR and NE-induced
excitability of this specific corticolimbic brain
region overlap.70,71 Together, these events
influence memory processing under stressful
circumstances such that the joint effect
appears to exceed normal memory processing
able to cause malignant forms of memory
underlying post-traumatic stress disorder. This
type of stress-related mood disorder is charac-
terised by enhanced emotional responsiveness
triggered by stimuli which are non- threaten-
ing at the time of perception but relate to dis-
tinct memories of a traumatic event in the
past.25,29
Environmental moderation ofbiological pathways
It is likely though that most of the genetic
associations previously described are not sole-
ly caused by sequence variation in specific
genes. First, evidence is accumulating that
such associations can be modified by environ-
mental exposures and life experiences to aug-
ment the genetic influence on mood behaviour
and susceptibility to depressive disorders,
albeit in an individual and gender specific
manner.1,28,39,72 Here, the ability of some inter-
actions to counterbalance the genetic influ-
ence by mediating adaptive changes in neuro-
biology leading to resilience should not be
overlooked in an effort to better understand
the neurobiology of stress-related mood disor-
ders.72 In particular, investigation of systems
biology driven polygenic risk mechanisms
need not be restricted to genetic (DNA
sequence variation) studies. Environmentally
induced epigenetic changes to the genome can
also regulate the functionality of gene products
by modulating gene expression and in turn
their protein levels, which would justify epige-
netic analysis of theoretically prioritised can-
didate genes. Epigenetic analysis refers to the
study of mitotically and/or meiotically heritable
changes in gene function that cannot be
explained by changes in DNA sequence in iso-
lation.73,74 Examples include methylation of
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the CpG dinucleotide of DNA and the covalent
modification of DNA-packaging histones.75,76
Together, epigenetic marks establish a macro-
molecular environment that controls the level
of underlying gene expression. Perhaps most
importantly, epigenetic marks appear
reversible, tissue specific and can be affected
by environmental changes (for example diet,
infection, toxins, social environment).77
Unfortunately for psychiatric and behaviour-
al genetic research, brain tissue is only avail-
able post mortem.78,79 Nevertheless, many stud-
ies have utilized this tissue in epigenetic stud-
ies.77,80,81 In addition, the applicability of alter-
native, more easily accessible peripheral tis-
sues instead, such as blood or cheek swabs, is
still under investigation and is likely to be gene-
dependent.82-85 A further consideration is that
both genetic and epigenetic variation in concert
are likely to contribute to disease. Therefore it
may be appropriate to study genetic variation
and epigenetic variation at the same locus in
the same individuals.67,86,87 This parallel
approach accentuates the place for epigenetics
alongside genetics in functional network or sys-
tems biology approaches to studying the molec-
ular psychoneurobiology of depression. 
Conclusions 
In this paper we have described an approach
to advancing research on genetic risk for
depression and related disorders based on a
detailed consideration of the neurobiology of
stress responsiveness. We have described the
physiological architecture of major neurobio-
logical systems underlying the stress response:
the HPA axis, the MCLS, the HARS and the RAS.
We have suggested that knowledge of interac-
tion between systems could be used to theoret-
ically group SNPs identified by genome-wide
association studies of depressive symptoms
into biologically meaningful polygenic profile
scores that can be tested in genetic epidemio-
logical designs. We have further suggested
that neurobiological knowledge of the stress
response could be used to prioritise genes for
more in depth investigation than genome-wide
marking can provide. This could extend to next
generation sequencing of genes that play rate-
limiting roles in neurosignalling within stress
response pathways. We have done this by
describing four principles for candidate gene
selection, which is based on the cumulative
weight of evidence for the role of the gene
products in each of these neurosignalling sys-
tems and as part of their interactions. Again,
neurobiological knowledge of interaction
between systems could be used to theoretically
group findings from this more in depth search
strategy. To illustrate a systems biology
approach we have presented findings from a
genetic investigation of temperamental risk
factors for depression using data on child
behaviour from the Western Australian Raine
Study. This example also illustrates the impor-
tance of phenotypic precision in detection of
polygenic risks, and the value of data from lon-
gitudinal study designs (with repeated meas-
ures of mood and behaviour) for improving
phenotypic outcomes. Our examples further
emphasised the potential importance of inter-
mediate traits or endophenotypes based on
distinction between specific complex disease
symptoms within a patient population, pre-dis-
ease traits or peripheral biomarker dynamics
in prospectively studied human cohorts. In the
specific context of genetic epidemiological
studies of stress-sensitive neurosignalling in
depression and anxiety, the cortisol awakening
response (as a reflection of an individual’s
stress reactivity) may be a relevant biological
endophenotype.88 Peripheral assessment of
morning stress hormone dynamics could con-
tribute to improved reproducibility within and
between longitudinal cohort studies of an
insightful biomarker-based intermediate phe-
notype in genetic causality studies. It is con-
ceivable that more refined definitions of study
outcomes in the form of endophenotypes will
optimise the detection of genetic aspects to
the etiology of psychopathology, identifying
susceptibility to the disease before clinical
diagnosis in those predisposed. 
In summary, we have argued that insight
into the functional neuroanatomy of the HPA
axis, MCLS, HARS and RAS provides an impor-
tant source of information for the prioritisa-
tion of genes of high significance to the psy-
choneurobiology underlying control of emo-
tional and behaviour, and therefore to the aeti-
ology of mental health problems. A theoretical
neuroscience framework complements the
hypothesis-free GWAS approach. It allows a
high likelihood of identification of those genes
that may be functionally related to the cause of
disease. There is a pressing need to further
develop and refine appropriate methods for
investigating polygenic risk in genetic epi-
demiology much better. 
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